During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

【导读】激素受体阳性（HR+）/人表皮生长因子受体2阴性（HER2-）乳腺癌是最常见的乳腺癌类型，持续复发仍是一个重要的临床问题。目前针对HR+/HER2-乳腺癌患者的复发预测模型仍存在局限性。整合多维数据是预测复发的一种有前途的替代方法。2025年 ...

Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2025, the Compensation ...